Q2 2025 Regenxbio Inc Earnings Call Transcript
Key Points
- Regenxbio Inc (RGNX) is accelerating the timeline for RGX-202, expecting to complete enrollment in the pivotal study by October 2025, ahead of schedule.
- The company has initiated commercial manufacturing for RGX-202, with a facility capable of producing up to 2,500 doses per year, positioning it well for market entry.
- Regenxbio Inc (RGNX) has a strong financial position with $364 million in cash and marketable securities, providing a runway into early 2027.
- The partnership with AbbVie for the development of CEROVEC in diabetic retinopathy is progressing, with a $100 million milestone payment secured upon the first patient dose in the Phase 2B/3 trial.
- The FDA has accepted the BLA for RGX-121 under the accelerated approval pathway, with a target decision date in November 2025, marking a potential first approval for Regenxbio Inc (RGNX).
- R&D expenses increased to $60 million for the quarter, up from $49 million in the same period last year, primarily due to manufacturing and clinical trial costs.
- The company faces risks and uncertainties related to forward-looking statements, which may cause actual results to differ from expectations.
- There is ongoing uncertainty in the DMD gene therapy space, which may impact the regulatory pathway and market dynamics for RGX-202.
- The need for a proactive immune suppression regimen for RGX-202 could be perceived as onerous by some patients and stakeholders.
- Regenxbio Inc (RGNX) is still exploring the potential for non-ambulatory patient inclusion in its Duchenne program, indicating that further development and regulatory discussions are needed.
Welcome everyone to the second-quarter 2025 the REGENXBIO earnings conference call. (Operator Instructions) Please note, slide reference during this call are available in the webcast and at the events page of REGENXBIO website.
At this time, I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of Regenxbio. Please go ahead.
Good morning and thank you for joining us today. Earlier this morning, Regenxbio released financial and operating results for the second quarter ended June 30, 2025. The press release is available on our website at www.regenxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans.
These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
